12:00 AM
Dec 03, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Alpha tocotrienol quinone: Phase IIb started

Edison began a double-blind, placebo-controlled, U.S. Phase IIb trial to evaluate thrice-daily 5 and 15 mg/kg EPI-743 for 6 months in about 30 patients ages 1-12 years. The trial includes a 6-month extension...

Read the full 141 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >